InvestorsHub Logo
Followers 14
Posts 2843
Boards Moderated 0
Alias Born 12/23/2014

Re: bigpike post# 111

Monday, 12/30/2019 3:45:59 PM

Monday, December 30, 2019 3:45:59 PM

Post# of 459
@pike

Quote from your post:
"Moreover, there is a chance that the current management team and board, which is impressive for a micro-cap, can create value by extending the use of their pumps for other emerging subcutaneous drugs. If I am right, the stock could have multiples of upsidefrom current levels"

Your post highlights a couple of things.
One, KRMD has an extremely talented and dedicated group(management and board) for a micro-cap. This is a team that can grow the company. The chairman of the board, John Fletcher, has made himself and others a lot of money by optimizing shareholder value!! (see link below)
Two, The potential for other, non plasma based drugs, going to subcutaneous infusions as the preferred manner of drug delivery is huge! Will this happen?? Who knows? The drivers to go to subcutaneous infusions remain the same. These include, cost savings, patient(or caretaker) convenience, and less toxicity do to drug level fluctuation in the body. It is a tantalizing thought to imagen that plasma based drug therapies are just the tip of the iceberg for subcutaneous infusions and KRMD.

https://www.businesswire.com/news/home/20190930005433/en/RMS-Medical-Products-Names-R.-John-Fletcher


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent KRMD News